+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Prils Market 2022-2026

  • PDF Icon

    Report

  • 120 Pages
  • January 2022
  • Region: Global
  • TechNavio
  • ID: 5531074
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the prils market and it is poised to grow by $ 784.14 mn during 2022-2026, progressing at a CAGR of 5.43% during the forecast period. Our report on the prils market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population and increase in chronic diseases. In addition, rising geriatric population is anticipated to boost the growth of the market as well.

The prils market analysis includes the application segment and geographic landscape.

The publisher's prils market is segmented as below:


By Application


  • Hypertension
  • Heart failure
  • Chronic kidney disorders

By Geographical Landscape


  • North America
  • Europe
  • Asia
  • ROW

This study identifies the sedentary lifestyle as one of the prime reasons driving the prils market growth during the next few years.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on prils market covers the following areas:
  • Prils market sizing
  • Prils market forecast
  • Prils market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading prils market vendors that include Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Fazio Group of Companies, Lupin Ltd., Manus Aktteva Biopharma LLP, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc. Also, the prils market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2021
  • Market outlook: Forecast for 2021 - 2026

Five Forces Analysis
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application
  • Market segments
  • Comparison by Application
  • Hypertension - Market size and forecast 2021-2026
  • Heart failure - Market size and forecast 2021-2026
  • Chronic kidney disorders - Market size and forecast 2021-2026
  • Market opportunity by Application

Customer landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2021-2026
  • Europe - Market size and forecast 2021-2026
  • Asia - Market size and forecast 2021-2026
  • ROW - Market size and forecast 2021-2026
  • Key leading countries
  • Market opportunity By Geographical Landscape
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Vendor Landscape
  • Landscape disruption

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Aurobindo Pharma Ltd.
  • Dr. Reddys Laboratories Ltd.
  • Fazio Group of Companies
  • Lupin Ltd.
  • Manus Aktteva Biopharma LLP
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2021 - 2026 ($ million)
13: Global market: Year-over-year growth 2021 - 2026 (%)
14: Five forces analysis 2021 & 2026
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2021
21: Application - Market share 2021-2026 (%)
22: Comparison by Application
23: Hypertension - Market size and forecast 2021-2026 ($ million)
24: Hypertension - Year-over-year growth 2021-2026 (%)
25: Heart failure - Market size and forecast 2021-2026 ($ million)
26: Heart failure - Year-over-year growth 2021-2026 (%)
27: Chronic kidney disorders - Market size and forecast 2021-2026 ($ million)
28: Chronic kidney disorders - Year-over-year growth 2021-2026 (%)
29: Market opportunity by Application
30: Customer landscape
31: Market share By Geographical Landscape 2021-2026 (%)
32: Geographic comparison
33: North America - Market size and forecast 2021-2026 ($ million)
34: North America - Year-over-year growth 2021-2026 (%)
35: Europe - Market size and forecast 2021-2026 ($ million)
36: Europe - Year-over-year growth 2021-2026 (%)
37: Asia - Market size and forecast 2021-2026 ($ million)
38: Asia - Year-over-year growth 2021-2026 (%)
39: ROW - Market size and forecast 2021-2026 ($ million)
40: ROW - Year-over-year growth 2021-2026 (%)
41: Key leading countries
42: Market opportunity By Geographical Landscape ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: Aurobindo Pharma Ltd. - Overview
50: Aurobindo Pharma Ltd. - Product and service
51: Aurobindo Pharma Ltd. - Key offerings
52: Aurobindo Pharma Ltd. - Key customers
53: Aurobindo Pharma Ltd. - Segment focus
54: Dr. Reddys Laboratories Ltd. - Overview
55: Dr. Reddys Laboratories Ltd. - Business segments
56: Dr. Reddys Laboratories Ltd. - Key offerings
57: Dr. Reddys Laboratories Ltd. - Key customers
58: Dr. Reddys Laboratories Ltd. - Segment focus
59: Fazio Group of Companies - Overview
60: Fazio Group of Companies - Product and service
61: Fazio Group of Companies - Key offerings
62: Fazio Group of Companies - Key customers
63: Fazio Group of Companies - Segment focus
64: Lupin Ltd. - Overview
65: Lupin Ltd. - Product and service
66: Lupin Ltd. - Key offerings
67: Lupin Ltd. - Key customers
68: Lupin Ltd. - Segment focus
69: Manus Aktteva Biopharma LLP - Overview
70: Manus Aktteva Biopharma LLP - Product and service
71: Manus Aktteva Biopharma LLP - Key offerings
72: Manus Aktteva Biopharma LLP - Key customers
73: Manus Aktteva Biopharma LLP - Segment focus
74: Merck KGaA - Overview
75: Merck KGaA - Business segments
76: Merck KGaA - Key offerings
77: Merck KGaA - Key customers
78: Merck KGaA - Segment focus
79: Novartis AG - Overview
80: Novartis AG - Business segments
81: Novartis AG - Key offerings
82: Novartis AG - Key customers
83: Novartis AG - Segment focus
84: Pfizer Inc. - Overview
85: Pfizer Inc. - Business segments
86: Pfizer Inc. - Key offerings
87: Pfizer Inc. - Key customers
88: Pfizer Inc. - Segment focus
89: Sun Pharmaceutical Industries Ltd. - Overview
90: Sun Pharmaceutical Industries Ltd. - Product and service
91: Sun Pharmaceutical Industries Ltd. - Key offerings
92: Sun Pharmaceutical Industries Ltd. - Key customers
93: Sun Pharmaceutical Industries Ltd. - Segment focus
94: Viatris Inc. - Overview
95: Viatris Inc. - Business segments
96: Viatris Inc. - Key offerings
97: Viatris Inc. - Key customers
98: Viatris Inc. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aurobindo Pharma Ltd.
  • Dr. Reddys Laboratories Ltd.
  • Fazio Group of Companies
  • Lupin Ltd.
  • Manus Aktteva Biopharma LLP
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.